Enzon, Inc.

Piscataway, NJ 08854

SBIR Award Summary

Total Number of Awards 5
Total Value of Awards $0.0
First Award Date 09/01/85
Most Recent Award Date 09/30/94

Key Personnel

Last Name Name Awards Contact
Abuchowski Abraham Abuchowski 3
Davis Frank F Davis 1
Hershfield Michael S Hershfield 1

5 Awards Won

Phase 1 STTR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/94 - 08/31/95

The long-term objective is to provide effective treatment for patients with severe, and presently untreatable, consequences of hyperuricemia. These patients are either hypersensitive to the xanthine oxidase inhibitor allopurinol, refractory to Conventional hypouricemic therapy, or use of allopurinol would interfere with necessary therapy for org...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/88 - 08/31/89

The enzyme superoxide dismutase (SOD) has been modified by the covalent attachment of monomethoxypolyethylene glycol (PEG) to form the conjugate PEG-SOD with greatly improved pharmacokinetics and clinically insignificant immunogenicity. Phase I trials have been completed in human volunteers with no adverse effects reported. PEG-SOD will be in e...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/15/87 - 06/14/88

Enzon is involved in the development of therapeutic enzymes for human and veterinary use. Many enzymes have shown effectiveness as anticancer agents on initial injection, but their immunogenicity and short plasma halflife have prevented exploitation of their potential. Enzon will modify two glutaminaseasparaginases and a histidase by our paten...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/15/86 - 02/14/87

Our long-term goal is to develop a therapeutic uricase that can be used in hyperuricemia and the various manifestations of gout, including gouty arthritis (acute and chronic) tophi and urate deposits in tissues and organs, and uric acid nephropathy. It is expected that the therapeutic uricase will be able to remove completely urate deposits in ...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/85 - 02/28/86

Active oxygen species are implicated in many diseases. Enzon is improving the therapeutic effectiveness of superoxide dismutase and catalase by our patented process so that these active oxygen scavenging enzymes can be used routinely against acive oxygen-induced or exacerbated pathologies. The improved enzymes are being submitted to a battery ...